Drug-Induced Kidney Injury Markers

## Overview

Serum creatinine, the standard measure of kidney function, does not rise until 50% or more of glomerular filtration is lost and is delayed 24-72 hours after injury onset. This "creatinine-blind" window allows nephrotoxic drug exposure to continue, worsening outcomes. Novel biomarkers aim to detect kidney injury hours after onset, localize the injury site, and guide timely intervention.

## Traditional Markers and Their Limitations

**Serum creatinine** reflects glomerular filtration rate (GFR) but is affected by age, sex, muscle mass, diet, and medications (trimethoprim and cimetidine inhibit tubular creatinine secretion, raising levels without true kidney injury). A 0.3 mg/dL increase defines Stage 1 AKI by KDIGO criteria.

**Blood urea nitrogen (BUN)** rises with dehydration, high-protein diet, GI bleeding, and catabolic states independent of kidney function. BUN/creatinine ratio >20:1 suggests pre-renal azotemia.

**Urine output** is a late and non-specific indicator. Oliguria (<0.5 mL/kg/hour for 6 hours) defines AKI but many patients maintain normal output during early nephrotoxic injury (non-oliguric AKI).

**Urinalysis** findings may suggest the mechanism: muddy brown granular casts in ATN, white blood cell casts in interstitial nephritis, and crystalluria in crystal nephropathy.

## Novel Urinary Biomarkers

**KIM-1 (Kidney Injury Molecule-1)** is a transmembrane protein undetectable in healthy kidneys but highly upregulated in injured proximal tubular cells. It is FDA-qualified for preclinical nephrotoxicity studies and rises within 12 hours of cisplatin or gentamicin injury, days before creatinine elevation. KIM-1 is the most validated proximal tubule injury biomarker.

**NGAL (Neutrophil Gelatinase-Associated Lipocalin)** is released from distal tubular and collecting duct cells within 2-4 hours of ischemic or nephrotoxic injury. It is one of the earliest detectable AKI biomarkers and is available as a point-of-care assay. NGAL rises before creatinine in contrast-induced nephropathy and aminoglycoside toxicity.

**Clusterin** is an anti-apoptotic glycoprotein upregulated in tubular injury. It is FDA-qualified for preclinical studies and may be particularly sensitive to drug-induced tubular dedifferentiation.

**L-FABP (Liver-type Fatty Acid Binding Protein)** is expressed in proximal tubules and released during oxidative stress and ischemia. Urinary L-FABP rises within hours of cisplatin exposure and predicts AKI severity.

## Biomarker Panels

No single biomarker captures all types of nephrotoxicity. The FDA and EMA have qualified panels combining KIM-1, NGAL, clusterin, and others for preclinical nephrotoxicity assessment. In clinical settings, the combination of KIM-1 (proximal tubule) + NGAL (distal tubule/collecting duct) + IL-18 (inflammasome activation) provides segment-specific injury detection.

**TIMP-2 x IGFBP7 (NephroCheck)** is the first FDA-approved AKI risk assessment test. It detects G1 cell cycle arrest in stressed tubular cells and predicts moderate-to-severe AKI within 12 hours.

## Key Takeaways

- Serum creatinine detects AKI only after >50% GFR loss with a 24-72 hour delay
- KIM-1 is the best-validated proximal tubule injury biomarker, rising hours after injury
- NGAL detects distal tubular injury within 2-4 hours
- NephroCheck (TIMP-2 x IGFBP7) is the first FDA-approved AKI prediction test
- Biomarker panels outperform single markers by localizing injury and predicting severity